The discovery of Human Epidermal growth factor Receptor 2 (HER2) positive breast cancer subtypes is not yet complete, according to Mark D. Pegram, MD, who will be delivering a presentation on the different clinical outcomes of these subtypes at the Miami Breast Cancer Conference this week.

Are genomic profiles refined enough that they should be used routinely to determine which breast cancer patients should receive adjuvant therapy? According to J. Michael Dixon, MD, who will be presenting the contra argument to this question in a debate at the Miami Breast Cancer Conference this week, the answer is: Not yet.

It’s very important to carefully analyze the data and weigh the pros and cons and the risk to benefits that exist within any study. Naturally, because mammography is such a widely used screening tool, it gets quite a bit of scrutiny. But it is all about the data, how it’s sliced and diced. Unfortunately many studies are not ideally run.

Clinicians often cite enhanced quality care, patient safety, and increased efficiencies as rationale for implementing electronic medical records. Those are strong reasons for interest in medical software. However, in a climate where reimbursements are falling, the cost and difficulty of EMRs can increasingly seem to be a barrier.

An exclusive podcast interview—Dr. Silver elucidates the current trends and therapies for treating various blood cancers.

In this exclusive CancerNetwork Blog podcast, nationally regarded healthcare specialist, Marty Neltner, talks about how given the current atmosphere in today's challenging healthcare market, community oncology practices need to be especially alert to future trends, one of which is value over volume.

Listen to internationally regarded oncologist and clinical investigator, Robert J. Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, discuss the past, present, and future trends in renal cell carcinoma.

In this exclusive ASCO podcast, Andrew J. Armstrong, MD, ScM, Assistant Professor of Medicine and Surgery Duke Comprehensive Cancer Center, Departments of Medicine and Surgery, Divisions of Medical Oncology and Urology, addressed the vexing clinical issue of chemotherapy’s limited effectiveness in advanced renal cell carcinoma.

Dr. Debu Tripathy, co-course director for the 27th Annual Miami Breast Cancer Conference sheds light on his presentation, The Role of Maintenance Therapy for Metastatic Breast Cancer, truly a complicated and controversial topic.